CFRX · Contrafect Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.87M | $4.87M | $5.29M | - | $10.81M | $16.76M | $12.72M | - | $8.66M | $7.78M |
| SG&A | $2.81M | $3.10M | $3.56M | - | $3.37M | $3.27M | $3.25M | - | $3.02M | $2.94M |
| Total Operating Expenses | $6.68M | $7.97M | $8.86M | - | $21.90M | $20.03M | $15.98M | - | $11.69M | $10.71M |
| D&A | - | - | $40.0K | - | - | - | $38.0K | - | - | - |
| Operating Income | ($6.68M) | ($7.97M) | ($8.86M) | - | ($21.90M) | ($20.03M) | ($15.98M) | - | ($11.69M) | ($10.71M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.36M) | ($7.57M) | ($1.37M) | - | ($17.07M) | ($18.09M) | ($20.16M) | - | ($5.29M) | ($5.40M) |
| EPS - Basic | ($0.50) | ($1.94) | ($0.69) | - | ($0.43) | ($0.14) | - | - | ($0.13) | - |
| EPS - Diluted | ($0.50) | ($1.94) | ($0.69) | - | ($0.43) | ($0.46) | - | - | ($0.13) | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.41M | $14.42M | $11.87M | $8.91M | $4.66M | $9.55M | $9.64M | $16.65M | $20.23M | $21.41M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.18M | $11.56M | $10.83M | $13.67M | $15.35M | $11.27M | $8.27M | $2.39M | $2.96M | $3.06M |
| Current Assets | $6.52M | $16.51M | $17.70M | $17.71M | $20.05M | $37.71M | $52.27M | $62.86M | $73.87M | $76.03M |
| Total Assets | $9.13M | $19.25M | $20.55M | $20.68M | $23.03M | $40.80M | $56.04M | $66.76M | $77.84M | $86.81M |
| Current Liabilities | $12.32M | $16.47M | $19.65M | $20.84M | $23.78M | $20.60M | $16.71M | $12.17M | $9.87M | $7.96M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.89M | $20.36M | $23.69M | $32.53M | $26.14M | $27.91M | $26.04M | $17.39M | $24.84M | $29.37M |
| Stockholders' Equity | ($5.76M) | ($1.11M) | ($3.14M) | ($11.85M) | ($3.10M) | $12.88M | $30.00M | $49.38M | $53.01M | $57.43M |
| Retained Earnings | ($340.00M) | ($334.64M) | ($327.08M) | ($325.70M) | ($315.87M) | ($298.80M) | ($280.71M) | ($260.55M) | ($256.15M) | ($250.86M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($8.80M) | - | - | - | ($11.77M) | - | - | - |
| Investing Cash Flow | - | - | $2.75M | - | - | - | $4.75M | - | - | - |
| Financing Cash Flow | - | - | $9.01M | - | - | - | - | - | - | - |
| CapEx | - | - | $5.0K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($8.80M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 6.42 | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -58.7% | -39.3% | -6.7% | - | -74.1% | -44.3% | -36.0% | - | -6.8% | -6.2% |
| Return on equity | 93.1% | 683.0% | 43.7% | - | 550.0% | -140.4% | -67.2% | - | -10.0% | -9.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.53 | 1.00 | 0.90 | 0.85 | 0.84 | 1.83 | 3.13 | 5.16 | 7.48 | 9.55 |
| Quick ratio | 0.53 | 1.00 | 0.90 | 0.85 | 0.84 | 1.83 | 3.13 | 5.16 | 7.48 | 9.55 |
| Cash ratio | 0.44 | 0.88 | 0.60 | 0.43 | 0.20 | 0.46 | 0.58 | 1.37 | 2.05 | 2.69 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.58 | -17.38 | -6.55 | -1.74 | -7.42 | 3.17 | 1.87 | 1.35 | 1.47 | 1.51 |
| Liabilities / Assets | 1.63 | 1.06 | 1.15 | 1.57 | 1.13 | 0.68 | 0.46 | 0.26 | 0.32 | 0.34 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 69.5% | 60.2% | 44.6% | - | -87.4% | -86.9% | -48.1% | - | -59.8% | -31.2% |
| Net income growth (YoY) | 68.6% | 58.2% | 93.2% | - | -222.5% | -235.2% | -288.0% | - | - | 69.4% |
| EPS growth (YoY) | -16.3% | -321.7% | - | - | -230.8% | - | - | - | 31.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -85.6% | - | - | - | - | -77.6% | -51.5% | 291.3% | 188.1% | 302.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CONTRAFECT Corp against the 5 most active filers in the same SIC group.